Receive The Newest Study Notifications

-- Data to be Featured in Oral Presentation at Clinical Trials on Alzheimer's Disease SEATTLE, WA, USA I October 2, 2019 I Athira Pharma, Inc., a clinical-stage company dedicated to developing first-in-class therapies for Alzheimer's and Parkinson's disease that are...

N-SIDE, provider of innovative software and strategic consulting services, announced that AstraZeneca has signed an agreement to implement the N-SIDE Suite for Clinical Trials. Within the scope of this agreement, AstraZeneca will use specifically the N-SIDE Supply and...

MONTREAL and CHARLOTTE, N.C., Oct. 3, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today...

Veeva SiteVault Free allows sites to manage regulatory documentation and study information for all trials Veeva aims to help industry accelerate clinical research and streamline study start-up and execution across sites and sponsors PLEASANTON, Calif.--(BUSINESS...

An early phase study was conducted in the U.S. in which different combinations of DNA (DNA-HIV-PT123) and protein (AIDSVAX® B/E) vaccines were administered in four randomized treatment groups (T1, T2, T3, T4), to determine which strategy would induce favorable...

MARLTON, N.J. & LONG BEACH, Calif.--(BUSINESS WIRE)--CNS Network (“CNS”) and Hassman Research Institute (“HRI”) have completed a strategic merger to form Apex Innovative Sciences, Inc. (“Apex” or the “Company”). The combination represents the industry-leading...

- Significant tumor regression observed with onvansertib in combination with standard-of-care paclitaxel in models of p53-mutated TNBC - Onvansertib preclinical data provides rationale for clinical trial targeting the 80% of TNBC that harbors the p53 mutation -...

Management will host its third quarter 2019 conference call on Monday, November 11, 2019 to provide a corporate update and review the Company's poster presentations from SITC HOLON, Israel, Oct. 2, 2019 /PRNewswire/ -- October 2, 2019 – Compugen Ltd. (CGEN), a...

Study evaluates clinical utility of 68Ga THP-PSMA PET/CT imaging in men with newly diagnosed and recurrent prostate cancer LONDON and BOSTON, Oct. 2, 2019 /PRNewswire/ -- Theragnostics, which is developing innovative radiopharmaceuticals to improve cancer diagnosis...

CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today FDA clearance to initiate enrollment in the...

Silicon Valley Bank and Oxford Finance to further strengthen our cash position.” EQUALISE is a Phase 1b multiple ascending dose trial that is evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD), and clinical activity of itolizumab in...

The Pitt Hopkins Research Foundation announces its first-ever human clinical trial to attempt to eradicate the severe gastrointestinal effects of Pitt-Hopkins syndrome (PTHS), a rare disorder caused by a mutation of the TCF4 gene (18 chromosome) and often classified...

Equillium, Inc. (NASDAQ: EQ) today announced it has initiated the EQUALISE Phase 1b clinical trial of itolizumab (EQ001) in patients with lupus nephritis and provided an update on its ongoing clinical programs. Additionally, Equillium announced an agreement with...

Preclinical and Phase 1 data support the evaluation of SRK-015 in ongoing Phase 2 trial for the treatment of patients with Type 2 and Type 3 spinal muscular trophy CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Scholar Rock (SRRK), a clinical-stage...

“If you have a patient who complains that their sleep has taken a turn for the worse then there is reason to open the door to a question about suicide,” says Vaughn McCall, MD, chair of the Department of Psychiatry and Health Behavior at the Medical College of Georgia...

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the initiation of dosing in the RAISE study, its global, pivotal, Phase 3 clinical trial evaluating zilucoplan for the treatment of generalized myasthenia gravis (gMG). “In a Phase 2 clinical trial, zilucoplan...

MOSAIC trial represents the first registrational trial for Proteus Syndrome and PIK3CA-related overgrowth spectrum BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL), today announced that the first patient was dosed in the registrational MOSAIC...

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, is pleased to announce it has been accepted for an oral presentation at the Society for Immunotherapy of Cancer...

Mark Terry for Biospace writes: It was a moderately busy week for clinical trial news. Here’s a look. Ipsen announced positive data from the ENGAGE Phase IIIb/IV clinical trial of Dysport (abobotulinumtoxinA) to treat upper and lower limb spasticity in adults with a...

Boston, MA – People who received omega-3 fish oil supplements in randomized clinical trials had lower risks of heart attack and other cardiovascular disease (CVD) events compared with those who were given placebo, according to a new meta-analysis from Harvard T.H....